|
Islet cell transplantation is the only known therapy that can reduce or
eliminate the side effects associated with many diseases. A search has been
on for an alternative site for islet transplantation as well as for an
optimal medical device in which to implant the islets. Several subcutaneous
devices have previously been developed for islet transplantation but from a
preclinical and clinical perspective the results from these products have
been generally disappointing.
Currently there is no approved device to house and protect therapeutic
cells in the body - cell therapy is limited to expensive procedures, poor
cell survival and inappropriate delivery as well as a lack of available
donors.
Sernova is a Phase I/II clinical stage company developing medical technologies
for the treatment of chronic debilitating metabolic diseases (Diabetes,
Hemophilia, Parathyroid, Parkinson’s) to replace proteins or hormones in
short supply within the body.
Sernova Corp. (TSX.V-SVA) has developed the subcutaneous Cell Pouch™ specifically
designed to overcome the issues with
previous implanted devices for cell transplantation. Sernova’s extensive
preclinical safety and efficacy studies have shown this device to be both
safe and effective, while being sparing of islets, supporting its design and
function.
I’ve been talking about, and buying shares in Sernova since June of 2009.
Yeah that’s right, almost five years.
And right now I’m as excited as when I first heard about SVA’s potential
disruptive life changing technology.
Why?
Well it’s not the fact the Cell Pouch works in pigs and rodents, it isn’t
the fact its bio-compatible and safe in humans.
Its Kevin Egan joining Sernova’s advisory board. And he didn’t just join
the business advisory board – he’s going to be the head guy, he’s going to
drive business development.
Over the last little while Sernova has surrounded itself with some serious
key players (Frank Holler, Nick Borrelly, Kevin Egan). Here we’ve got guys
who kicked around Sernova’s technology for months before getting on board
with us.
Frank Holler even went so far as meeting with two of North America’s most
respected islet researchers in the world whilst performing his diligence on
the science, including a meeting with Dr. Shapiro in
Edmonton.
Kevin Egan might be the key though, he would have to be considered the
‘Wayne Gretzky’ of the pharma world.
Egan has taken a couple of drugs to market and made them blockbusters:
“He has been directly involved in helping to develop blockbuster drugs
from two, bell-weather US biotech giants: Amgen and Icos.”
Egan doesn’t have to be here, he wants to be here, he believes Sernova’s
Cell Pouch is a disruptive technology and he wants to ‘lead the charge.’
Your author, whose also an SVA shareholder, believes Kevin’s acceptance of
the lead role in SVA’s business development signals to sophisticated
investors that a sea change in the way Sernova’s technology is viewed by the
market is imminent.
I’ve never questioned the science, never doubted Phillip’s commitment. We
have the science, we have our business development lead, we have our own
dream team.
I’m not selling and Ray Matthews
has hundreds of thousands of shares stacked on the buy side. Those are his
bids at .20 & .19.
I’ve had a lot of huge ‘wins’ over the years and so has Ray, we both
believe Sernova Corp. TSX.V-SVA is going to be our biggest winner yet.
SVA needs to be on your radar screen. Is Sernova on your screen?
If not, maybe it should be.
Richard lives with his family on a 160 acre
ranch in northern British Columbia. He invests in the resource and
biotechnology/pharmaceutical sectors and is the owner of Aheadoftheherd.com.
His articles have been published on over 400 websites, including:
WallStreetJournal, USAToday, NationalPost, Lewrockwell,
MontrealGazette, VancouverSun, CBSnews, HuffingtonPost, Beforeitsnews,
Londonthenews, Wealthwire, CalgaryHerald, Forbes, Dallasnews, SGTreport,
Vantagewire, Indiatimes, Ninemsn, Ibtimes, Businessweek, HongKongHerald,
Moneytalks, SeekingAlpha, BusinessInsider, Investing.com and the Association
of Mining Analysts.
Please visit www.aheadoftheherd.com
If you are interested in advertising on Richard’s site please contact
him for more information, rick@aheadoftheherd.com
***
Legal Notice / Disclaimer
This document is not and should not be construed as an offer to sell
or the solicitation of an offer to purchase or subscribe for any investment.
Richard Mills has based this
document on information obtained from sources he believes to be reliable but
which has not been independently verified.
Richard Mills makes no guarantee,
representation or warranty and accepts no responsibility or liability as to
its accuracy or completeness. Expressions of opinion are those of Richard
Mills only and are subject to change without notice. Richard Mills assumes no
warranty, liability or guarantee for the current relevance, correctness or
completeness of any information provided within this Report and will not be
held liable for the consequence of reliance upon any opinion or statement
contained herein or any omission.
Furthermore, I, Richard Mills,
assume no liability for any direct or indirect loss or damage or, in
particular, for lost profit, which you may incur as a result of the use and
existence of the information provided within this Report.
|
